lOMoARcPSD|58511717
NR546 W3 Antipsychotics Table-1
Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner (Chamberlain
University)
Scan to open on Studocu
Studocu is not sponsored or endorsed by any college or university
Downloaded by Samuel Kinyanjui ()
, lOMoARcPSD|58511717
Drug name Indication Half-life (T1/2), Notable side effects (associate to pathway
Target symptoms: state if positive or negative metabolism (CYP 450 or NT)
effect enzyme)
Potency (if noted. receptor occupancy if noted)
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Indication: Manifestations of psychotic disorders Half Life: Decanoate half- Notable Side Effects: Neuroleptic induced
Tics and vocal utterances in Tourette's syndrome life approximately 3 deficit syndrome
Second line treatment of severe behavior problems weeks Akathisia
in children of combative explosive hyper excitability Oral half-life Drug induced parkinsonism
Treatment of schizophrenic patients who require approximately 12 to 38 Tardive dyskinesia tardive dystonia
prolonged parenteral antipsychotic therapy hours Irreversible involuntary dyskinetic
Bipolar disorder Metabolism: movements
Behavioral disturbances in dementias CYP1A2 Galactorrhea, amenorrhea
Delirium in conjunction with lorazepam CYP2D6 Dizziness, sedation
Target Symptoms: Positive effect on reducing CYP3A4. Dry mouth
positive symptoms in schizophrenia, including Constipation
hallucinations and delusions. Urinary retention
Potency: High potency first generation Blurred vision
Neurotransmitter (s) Affected: Blocks dopamine 2 Decreased sweating
receptors, reducing positive symptoms of psychosis Hypertension
and possibly combative explosive and hyperactive Tachycardia
behaviors Hypotension
Blocks dopamine 2 receptors in the nigrostriatal Weight gain.
pathway improving ticks and other symptoms in
Tourette syndrome.
Thioridazine Schizophrenic patients who fail to respond to Half Life: 21 to 48 hours Notable Side Effects: Neuroleptic induced
treatment with other antipsychotic drugs deficit syndrome
Motor and autonomic hyperactivity Metabolism: CYP450, Akathisia
Violent or aggressive behavior CYP2D6 Priapism
Potency: Low potency first generation Drug induced parkinsonism
Neurotransmitter (s) Affected: Blocks dopamine 2 Tardive dyskinesia
, lOMoARcPSD|58511717
receptors reducing positive symptoms of psychosis Irreversible involuntary dyskinetic
she movement
Galactorrhea, amenorrhea
Pigmentary retinopathy at high doses
Dizziness, sedation
Dry mouth
Constipation
Blurred vision
Sexual dysfunction
Weight gain
Hypotension
Thiothixene Indication: schizophrenia, other psychotic Half Life: 34-35 hours Neuroleptic induced deficit syndrome
disorders, bipolar disorder. Akathisia
Target Symptoms: Positive effects on positive Metabolism: CYP1A2 drug induced parkinsonism
symptoms in schizophrenia. Reduces symptoms of Tardive dyskinesia
acute psychotic mania. Reduces negative symptoms Irreversible involuntary dyskinetic
of psychosis movement
Potency: High potency conventional antipsychotic Galactorrhea, amenorrhea
Neurotransmitter (s)affected: blocks dopamine 2 Sedation
receptors, reducing positive symptoms of psychosis Dry mouth
Constipation
Vision disturbance
Urinary retention
Hypertension
Tachycardia
Rare fine lenticular pigmentation
Fluphenazine Indication: Psychotic disorders Half-life: 14 to 16 hours Neuroleptic induced deficit syndrome
bipolar disorder Akathisia
Target Symptoms: Effective on positive symptoms Metabolism: CYP2D6 Drug induced parkinsonism
of psychosis Tardive dyskinesia
Motor and autonomic hyperactivity Irreversible involuntary dyskinetic
Violent or aggressive behavior movements
Potency: High potency conventional antipsychotic Galactorrhea amenorrhea
Neurotransmitter (s) Affected: Blocks dopamine 2 Dizziness, sedation
NR546 W3 Antipsychotics Table-1
Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner (Chamberlain
University)
Scan to open on Studocu
Studocu is not sponsored or endorsed by any college or university
Downloaded by Samuel Kinyanjui ()
, lOMoARcPSD|58511717
Drug name Indication Half-life (T1/2), Notable side effects (associate to pathway
Target symptoms: state if positive or negative metabolism (CYP 450 or NT)
effect enzyme)
Potency (if noted. receptor occupancy if noted)
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Indication: Manifestations of psychotic disorders Half Life: Decanoate half- Notable Side Effects: Neuroleptic induced
Tics and vocal utterances in Tourette's syndrome life approximately 3 deficit syndrome
Second line treatment of severe behavior problems weeks Akathisia
in children of combative explosive hyper excitability Oral half-life Drug induced parkinsonism
Treatment of schizophrenic patients who require approximately 12 to 38 Tardive dyskinesia tardive dystonia
prolonged parenteral antipsychotic therapy hours Irreversible involuntary dyskinetic
Bipolar disorder Metabolism: movements
Behavioral disturbances in dementias CYP1A2 Galactorrhea, amenorrhea
Delirium in conjunction with lorazepam CYP2D6 Dizziness, sedation
Target Symptoms: Positive effect on reducing CYP3A4. Dry mouth
positive symptoms in schizophrenia, including Constipation
hallucinations and delusions. Urinary retention
Potency: High potency first generation Blurred vision
Neurotransmitter (s) Affected: Blocks dopamine 2 Decreased sweating
receptors, reducing positive symptoms of psychosis Hypertension
and possibly combative explosive and hyperactive Tachycardia
behaviors Hypotension
Blocks dopamine 2 receptors in the nigrostriatal Weight gain.
pathway improving ticks and other symptoms in
Tourette syndrome.
Thioridazine Schizophrenic patients who fail to respond to Half Life: 21 to 48 hours Notable Side Effects: Neuroleptic induced
treatment with other antipsychotic drugs deficit syndrome
Motor and autonomic hyperactivity Metabolism: CYP450, Akathisia
Violent or aggressive behavior CYP2D6 Priapism
Potency: Low potency first generation Drug induced parkinsonism
Neurotransmitter (s) Affected: Blocks dopamine 2 Tardive dyskinesia
, lOMoARcPSD|58511717
receptors reducing positive symptoms of psychosis Irreversible involuntary dyskinetic
she movement
Galactorrhea, amenorrhea
Pigmentary retinopathy at high doses
Dizziness, sedation
Dry mouth
Constipation
Blurred vision
Sexual dysfunction
Weight gain
Hypotension
Thiothixene Indication: schizophrenia, other psychotic Half Life: 34-35 hours Neuroleptic induced deficit syndrome
disorders, bipolar disorder. Akathisia
Target Symptoms: Positive effects on positive Metabolism: CYP1A2 drug induced parkinsonism
symptoms in schizophrenia. Reduces symptoms of Tardive dyskinesia
acute psychotic mania. Reduces negative symptoms Irreversible involuntary dyskinetic
of psychosis movement
Potency: High potency conventional antipsychotic Galactorrhea, amenorrhea
Neurotransmitter (s)affected: blocks dopamine 2 Sedation
receptors, reducing positive symptoms of psychosis Dry mouth
Constipation
Vision disturbance
Urinary retention
Hypertension
Tachycardia
Rare fine lenticular pigmentation
Fluphenazine Indication: Psychotic disorders Half-life: 14 to 16 hours Neuroleptic induced deficit syndrome
bipolar disorder Akathisia
Target Symptoms: Effective on positive symptoms Metabolism: CYP2D6 Drug induced parkinsonism
of psychosis Tardive dyskinesia
Motor and autonomic hyperactivity Irreversible involuntary dyskinetic
Violent or aggressive behavior movements
Potency: High potency conventional antipsychotic Galactorrhea amenorrhea
Neurotransmitter (s) Affected: Blocks dopamine 2 Dizziness, sedation
